Podcasts about Cart

For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases. But the application of these engineered cell therapies is expanding to reset the immune system for patients living with lupus, stiff person syndrome and other autoimmune conditions. And with new frontiers come new rules. In this week’s episode of "The Top Line," Fierce Pharma’s Angus Liu chats with Harpreet Singh, M.D., chief medical officer at Precision for Medicine and a former director of the FDA's Division of Oncology, about a recent article by FDA officials led by CBER Director Vinay Prasad, M.D., laying out the agency’s perspective on its regulation of autoimmune CAR-T therapies. Singh discusses how the agency’s "case-by-case" approach, as indicated in the article, could be similar to—and different from—CAR-T for oncology indications. She also talks about how drug developers should follow existing development experience, as well as prepare for specific requirements for long-term patient follow-up and potential new clinical endpoints from the agency. To learn more about the topics in this episode: FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial See omnystudio.com/listener for privacy information.

La ciencia española lidera mundialmente los trasplantes. Amelia Escolano, desde Filadelfia, investiga una innovadora vacuna contra el VIH que induce anticuerpos neutralizantes y muestra potencial para otros virus mutantes. España también deposita semillas de olivo en Svalbard para preservar la diversidad genética agrícola. Las enfermedades raras encuentran esperanza en la terapia génica. La Fundación Columbus impulsa esta técnica que corrige información genética defectuosa con éxitos en patologías monogénicas, aunque el coste y la falta de ánimo de lucro para casos ultrarraros son desafíos. Las terapias CAR-T, llamados "medicamentos vivientes", prometen contra el cáncer al modificar células T del paciente para atacar tumores. Tenerife registra un enjambre sísmico en el Teide, bajo vigilancia y sin indicios de erupción inminente. En economía, la inflación española se mantiene en el 2.3% en febrero (subyacente 2.7%), superando la media europea, afectando la competitividad con alimentos ...

Au sommaire : Netflix refuse de relever son offre pour le rachat du groupe Warner Bros Discovery, ouvrant la voie à Paramount Skydance qui propose une valorisation de 110 milliards de dollars pour le groupe.L'Ukraine ouvre une usine de production de drones au Royaume-Uni, un investissement de 230 millions d'euros pour sécuriser la production et répondre aux besoins de ses troupes.Stellantis enregistre une perte record de 22,3 milliards d'euros en 2025, liée à des charges de repositionnement stratégique du groupe.Malgré une baisse des ventes de 2%, l'équipementier automobile Valeo affiche un bénéfice de 200 000 euros et prévoit une hausse de 23% de son bénéfice en 2025.La SNCF dégage un bénéfice de 1,8 milliard d'euros en 2025 grâce à un retour du trafic passager à des niveaux d'avant-Covid.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Procurez-vous le livre de Fabien OlicardToutes les infos sur son site fabienolicard.fr--COACHING RELATION À L'ARGENT

CAR T‑cell therapy is redefining what personalized cancer treatment can look like, offering real promise for patients and families. In this episode, we speak with Dr. Richard Maziarz and CAR T Nurse Coordinator Bashi Ratterree of Oregon Health & Science University (OHSU). Together, they explain how CAR T‑cell therapy works, who may be eligible, what patients can expect during treatment and recovery, and the promising advancements shaping the future of this innovative therapy. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: CAR T-cell therapy Clinical Trial Support Center CAR T-Cell Therapy: A Path of Hope and Healing Video Series Bloodline Breakthroughs: innovations and inspiration video podcast: CAR T-cell Therapy Hematology Horizons vlog: CAR T-Cell Therapy and the Patient Experience CAR T-Cell Therapy: Side Effects video Additional Blood Cancer United Support Resources: Information Specialists Financial support Online Chat Free Nutrition Consultations Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; Kite, a Gilead Company; Novartis Pharmaceuticals Corporation. The post Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives first appeared on The Bloodline with Blood Cancer United Podcast.

Bhavana (Tina) Bhatnagar, DO—Associate Professor of Medicine at the WVU Cancer Institute—shares her journey from academic centers to rural West Virginia, where she's working to expand access and improve outcomes for underserved communities. We talk about what high-quality rural cancer care really takes: overcoming transportation and financial barriers, navigating limited specialty resources, building community-based clinical trials, and expanding access to innovations like CAR T—powered by strong multidisciplinary teams.Key takeaway: the best care starts with understanding the person behind the patient.

This review series focuses on recent advances in resolving macro and molecular structures that have driven the field of occlusive thrombus structure and function forward. Covering multiple contributions to thrombosis, eg, platelets, factor XIII, and the contact system, the series also looks to put this new knowledge into the context of future advances in diagnostic and therapeutic tools to enhance normal hemostasis while preventing and treating unwanted thrombosis. Blood Associate Editor, Dr. Thomas Ortel discusses this series with Drs. Alisa Wolberg, Jonas Emsley, and John Weisel, who all contributed to articles in the Review Series on the Structural Underpinnings of Hemostatic Plugs and Thrombotic Occulsions which can be found in volume 146, issue 12 of Blood. 

Convidada: Marina Pera, analista sênior de risco político da consultoria Control Risks no México. O chefão do cartel Jalisco Nova Geração, um dos mais violentos e poderosos grupos criminosos organizados do México, foi morto no último domingo (22). O megatraficante Nemesio Oseguera Cervantes, conhecido como "El Mencho", foi baleado em uma operação das forças de segurança mexicanas: os agentes monitoraram os passos de sua namorada até uma cabana em Tapalpa, na região montanhosa do estado de Jalisco, onde se deu o confronto. A morte de El Mencho foi o gatilho para uma reação violenta do grupo organizado. Ataques foram registrados em 20 estados mexicanos: criminosos incendiaram veículos, bloquearam rodovias, fecharam escolas e espalharam pânico. O número de mortos já passa de 70, entre policiais, agentes penitenciários e integrantes do cartel. O governo mobilizou mais de 10 mil militares para conter a violência. A morte do chefe do Jalisco Nova Geração abre uma nova fase de incertezas no México, afirma Marina Pera, analista sênior de risco político da consultoria Control Risks no México. Em entrevista a Natuza Nery, ela descreve como El Mencho mantinha seu poder e cultivava uma imagem messiânica diante de seu grupo. Marina também explica por que a queda de uma liderança desse tamanho pode desencadear uma avalanche na estrutura do narcotráfico e nas instituições oficiais mexicanas.

Guest: Dr. Ido Amit is a Principal Investigator and the Eden and Steven Romick Professorial Chair at the Weizmann Institute of Science. His lab is at the forefront of developing and applying cutting-edge single-cell genomics technologies alongside advanced computational approaches. By integrating these innovative tools in both animal models and human studies, his team uncovers the immune regulatory mechanisms and pathways that shape health and disease. Featured Products and Resources: Stay up-to-date with the latest in human immunology news. Download a free wallchart on the production of CAR T cells. The Immunology Science Round Up Modified RNA Prevents Autoimmunity – Researchers show that modified RNA from our own cells naturally blocks TLR7 and TLR8, preventing harmful immune activation. Oncolytic Virus Boosts T Cells – In glioblastoma patients, a single virus treatment helped the immune system attack the tumor. Rewiring the Immune System During Food Scarcity – When food is scarce, stress hormones rebalance the immune system to fight infection while conserving glucose and preserving immune memory. Regulating Bystander T Cells – IL-4 can dial down how strongly memory CD8+ T cells respond to infection without direct antigen stimulation. Image courtesy of Dr. Ido Amit Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

BUFFALO, NY – February 25, 2026 – A new #editorial perspective was #published in Volume 17 of Oncotarget on February 20, 2026, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.” Led by Uzma Saqib — with corresponding author Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya — the perspective reviews recent clinical and translational advances in chimeric antigen receptor T-cell (CAR-T) therapy and highlights both its promise and its remaining barriers. The piece synthesizes recent clinical advances in hematologic malignancies and emerging applications in solid tumors, while focusing attention on safety (for example, cytokine release syndrome and neurotoxicity), resistance, antigen specificity, and access disparities. The authors summarize the CAR-T workflow (leukapheresis → genetic modification and expansion → infusion) and note major recent clinical gains — including improved outcomes in leukemia, lymphoma, and multiple myeloma — that support wider adoption of cellular immunotherapy approaches. They emphasize that despite these advances, important clinical challenges remain, particularly for solid tumors, where antigen selection, tumor microenvironment, and T-cell trafficking limit efficacy. At the same time, the perspective highlights technological and clinical strategies under development to overcome these obstacles, including next-generation CAR designs and improved supportive-care protocols. “Despite its promise, CAR T-cell therapy faces several critical challenges.” The authors call out clear next steps for the field: (1) continued refinement of CAR constructs (dual-targeting, switchable/on-off systems, armored CARs) to improve specificity and reduce on-target/off-tumor toxicity; (2) improved management protocols and prophylactic measures to mitigate CRS and neurotoxicity; (3) expanded investigation of allogeneic or alternative CAR-T platforms to address manufacturing, cost, and access barriers; and (4) focused translational studies to improve T-cell trafficking and efficacy in solid tumors. They also highlight equity issues — socioeconomic and racial disparities that limit access to CAR-T — and urge that broad deployment plans include strategies to expand availability and affordability. DOI - https://doi.org/10.18632/oncotarget.28836 Correspondence to - Krishnan Hajela - hajelak@gmail.com Abstract video - https://www.youtube.com/watch?v=T4hbwPToVKI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28836 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, CAR-T therapy, therapeutic approaches To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Immune discusses how tattoo ink accumulates in lymph nodes, promotes inflammation and influences response to two different vaccines. Hosts: Vincent Racaniello, Cindy Leifer, Stephanie Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server IL-9, CAR T cells and anti-tumor CD8 cells Tattoo ink, inflammation and vaccines Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

Erick, Rock, Carcará, Batata, Coptulio, Miqueias, Villas Boas e Paganotto se reúnem para o Fala Glauber News. O programa vai ao ar segundas, quartas e sextas, das 16h00 às 20h00.QUER FAZER PARTE DISSO? ENTÃO BOOORAAA. VEM COM A GENTE E INTERAJA NESSA TRANSMISSÃO AO VIVO!!!VIIIIIIIIBRA!!! INSCREVA-SE NO NOSSO NOVO CANAL:  @falaglaubernews  CONHEÇA MAIS DOS NOSSOS PATROCINADORES:

This month, the gals welcome back their pal Robbie Knutsen to scream about mermaids in public, niche children's birthday party themes, Pentagon plugs, twisted panties, crocodile tears, and modern grave robbing. Tune in for February's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.   0:00 Introduction 11:26 Headlines 45:24 Coven Confessions 1:16:15 Coroner Corner

…ON TODAYS PROGRAM…   FERNANDO AND THE HONDA CURSE, LAWRENCE STROLL SELLS ASTON MARTIN NAMING RIGHTS FOR 50 MILLION POUNDS. FERRARI ON THE OTHER HAND SHOW OFF NEW SPINNING REAR WING AND, LOOK VERY COMPETITIVE ! MCLAREN AND MERCEDES ARE NOT FAR BEHIND… RED BULL IS STILL A QUESTION MARK?…AND FERNANDO WILL NEED HIS CAMPING CHAIR AS THE GP2 ENGINE THAT FAILED HIM AT MCLAREN, THAT WENT KABLAMO IN THE INDY 500 AND LOOKS TO HAUNT ALONSO FOR ANOTHER LONG SEASON!! STAY TUNED FOR SOME GREAT ONE LINERS FROM MACHISMO… THIS WEEK'S NASIR HAMEED CORNER…MORE VINTAGE BANTER BETWEEN THE HOST AND NASIR…THIS WEEKS SPECIAL GUEST: MARCUS ERICSSON, MARTIN BRUNDLE, AND MIKI MONRAS DE ESPANA…! Indianapolis 500 Veteran Hucul Dies at 79   INDIANAPOLIS (Friday, Feb. 20, 2026) – Canadian driver Cliff Hucul, a veteran of three Indianapolis 500 starts in the late 1970s, died Feb. 17 on his farm in his native Prince George, British Columbia. He was 79. Hucul made three consecutive starts in “The Greatest Spectacle in Racing” from 1977-79. His best finish came as a rookie in 1977, 22nd in the No. 29 Team Canada McLaren/Offenhauser that Hucul bought after Johnny Rutherford drove it to victory in the 1976 “500.” Hucul completed 72 laps before being sidelined by gearbox problems. He qualified on Bump Day for that race despite touching the wall in practice the previous day and suffering two engine failures during the Month of May, a significant pitfall for his low-budget team. Hucul's best qualifying spot was 18th in 1979, his final “500” start. The small-town driver from northern British Columbia learned his craft by racing stock cars and modified sprint cars at local tracks. He then began racing modifieds and supermodifieds in the Pacific Northwest against drivers that included eventual Indianapolis 500 winner and INDYCAR SERIES champion Tom Sneva and his brother Jerry Sneva. Hucul made 24 total USAC and CART starts between 1977-81, with eight top-10 finishes. Hucul's best finish in the standings was 11th in 1979, when he started the season by placing fifth at Ontario Motor Speedway and a career-best fourth at Texas World Speedway. In 1996, Hucul became a paraplegic after an automobile accident when crossing black ice on a highway in British Columbia. Despite being confined to a wheelchair, Hucul remained active, managing his farm and mentoring many drivers in the area. He was inducted into the Prince George Sports Hall of Fame for his lifetime contributions to auto racing. Hucul is survived by his son, Kelly, and daughter-in-law, Sylvie; daughter, Michele, and many grandchildren. 2026 BAHRAIN TESTING - WEEK 1, DAY 3 MAX VERSTAPPEN “Looking at the test overall, the Team got in a good number of laps on the first day so we were happy with that. We completed a lot of things that we wanted to test with the new Power Unit and the car in general. Today it was a continuation of that plus also trying to explore a little bit more with the car; you go through so many test items that it continues to change and evolve with everything that you are testing. In general, it is all so new that we are still learning a lot, but the car was good. We also have new tyres, so we spent some time looking at different sets and understanding what we need to improve and be better at. With the power unit, looking at the laps we got on the board, the start that we have had is good. That's exactly what we wanted to do and it was not a given. Whether it will be enough to win races, we don't know, we will just focus on ourselves and try to do the best we can, but there is still massive room for improvement. Finally, with the car, we learnt a lot about what worked and what didn't. Our runs also gave us even more ideas for the afternoon with Isack and then for next week, where we can continue to try new things and different set ups.” ISACK HADJAR “The first week here in Bahrain has gone well. Of course, I had to wait a little before getting in the car after Barcelona, but once I did, we were able to put it to the test and really work through what we need ahead of next week and Melbourne. There are so many things to look at, but we're staying on track with our programme so far. True performance and pace are always hard to judge in pre-season, but we can be happy with the reliability we've had from the power unit this week. There are still things to work on in terms of balance and tyre management, but that's completely normal for this time of year. We're working through it together as a Team to get where we want to be for Australia. I've known the people here for a while now, but it's great to be working with them again in an environment like this." ASTON MARTIN The Aston Martin Aramco Formula One™ Team concluded its testing programme at the Bahrain International Circuit today, with Lance Stroll returning to the cockpit of the AMR26 for the final time before the Australian Grand Prix. Lance did not get on track until late in the morning session due to a battery-related issue that had impacted Fernando's running yesterday. Honda carried out simulations on the test bench at HRC Sakura before the car returned to the track. Due to a shortage of power unit parts, the run plan was very limited and consisted only of short stints. Lance Stroll “It's been a challenging couple of weeks here in Bahrain, and today's limited running wasn't the way we wanted to finish the second test. It's clear the car isn't where we want it to be performance-wise, and we know there's a lot of work ahead in the coming weeks and months. There's a long season ahead, and we'll keep pushing flat out to unlock more performance. I want to say a big thank you to everyone trackside and back at the AMRTC for the work that's gone in so far. It's not where we want to be right now, but I know how determined this team is. We'll stick together, rise to the challenge and keep working until we deliver the performance we are looking for.” WILLIAMS F1 2026 Bahrain pre-season testing – Day 3 James Vowles, Team Principal: Another solid day of running and mileage. It's great to see that across the last six days of testing, we've been predominantly tyre and time limited, and able to complete the full programme that we wanted. That's just a testament to the hard work of the teams, both here and in Grove, making sure that we made up for lost time. 
 No one truly knows where all the performance lies. That's what Melbourne is all about, so I can't wait to go there, to gain a further understanding of where we are. What I know for sure, though, is we have work to do. There's no doubt about it. We've put ourselves on the back foot. But my assurance to everyone is that we have an aggressive programme lining up in front of us in order to make sure that we extract as much performance in this car as possible over the forthcoming months. Carlos Sainz: The past six days of testing in Bahrain has been one of the most interesting and challenging tests that I've been part of, given the new regulations and number of things we had to learn. The progress from day one has been significant, although there are still going to be things to understand and solve at the start of the season. We go into the first half of the year with lower expectations than 2025 knowing that we'll be starting slightly on the back foot. However, I'm really looking forward to getting started and focusing on improving the cars through the year to become more competitive. Bring on Melbourne! Alex Albon: It's been a relatively smooth test here in Bahrain. We got some good mileage under our belts and tested everything we wanted to get out of the car, so I'm feeling more ready for Melbourne. There's still a lot we need to understand and plenty of performance left on the table that we need to extract, but I'm glad the tests went to plan. It's now all about maximising the next few days to prepare for the first race of the year! THIS WEEK'S INTERVIEW WITH MIKI MONRAS... Miki Monrás on battling Bottas and Ricciardo in the late 2000s and the rising cost of junior racing In the late 2000s, Miki Monrás was one of Spain's brightest prospects on the junior single-seater ladder, trading blows with the likes of Daniel Ricciardo, Valtteri Bottas and António Félix da Costa in Formula Renault and GP3. But while his rivals pushed on towards F1 or careers in GTs, the Spaniard's single-seater journey came to an abrupt halt in 2011. Feeder Series caught up with Monrás to reflect on the times he rubbed shoulders with greatness, the challenges of racing in the post–financial crisis era, and life beyond motorsport. By Anabelle Bremner Back in the noughties, the path from karting to Formula 1 looked nothing like it does today. There was no standardised Formula 4, no carefully managed ladder – just a patchwork of championships that rewarded those brave enough, and wealthy enough, to dive straight in. Eurocup Formula Renault 2.0 was as deep as it got: 40-car grids stacked with future stars, the proving ground where Pierre Gasly, Nyck de Vries and Lando Norris would come to cut their teeth. But before all of them, it was Monrás in the thick of it. He made his single-seater debut in late 2007, the result of years spent chasing speed. His first taste of racing, in fact, came on two wheels – on a motocross bike, inspired by his father, who had raced professionally in Spain and Europe. At the age of eight, Monrás joined a motocross camp, and it wasn't long before karting came calling. “After the first race, I really enjoyed it,” he recalls. “I remember it was Christmastime and I asked for a motocross scooter and for a go-kart. So I finally got the go-kart, and that's the way I started. Then I started racing in Catalonia, and I just moved through Spain and Europe and all the world championships until formula.” Single-seater racing, however, would prove a unique beast. Shortly before turning 16, Monrás moved straight from karting into Formula Renault 2.0, in which the competition was fierce. “Normally at that age you'd go before to a category not straight to 2.0,” he said. “My first year I was racing with Bottas, I was racing with Ricciardo, I was racing with [Andrea] Caldarelli – really good drivers.… I was racing against people that were already racing for two years in single-seaters. That was a big difference.”His first Eurocup campaign, in 2008, proved a challenging one. He was scoreless for his first five rounds with the Hitech Junior Team (no relation to the current Hitech) before a switch to SG Formula brought him six points in the final two rounds. Valtteri Bottas, then of Motopark Academy, went on to claim that year's title after a close fight involving Ricciardo, Caldarelli and Roberto Merhi. The next year brought Monrás a decidedly better season and three podiums with SG Formula, owned by Mercedes Junior Team advisor Stéphane Guerin. He wound up fifth overall in a season dominated by a fierce three-way fight between Félix da Costa, Jean-Éric Vergne and Albert Costa – the last of whom ultimately took the title. Racing against so much talent at such a young age left Monrás with plenty of perspective on what might have been. “Ricciardo was my teammate. Jean-Éric Vergne was my teammate. I raced with Da Costa, Bottas, with Magnussen, so many people that have been racing each other and winning races,” he said. “[I] think if I changed something at that point, maybe I would be in Formula 1, but who knows. Maybe yes, maybe no. “But at that time, it was really difficult times because it was 2010, '11, '12, where there was also a big crisis in the world, especially in Europe. It was really difficult for Spanish drivers to get the sponsors and the money to race.” The financial squeeze triggered by the 2008 global financial crisis left Monrás and many of his peers in a precarious position. Several teams, such as SG Formula, shut their doors in the wake of the crisis amidst an already shifting landscape in junior racing. “It's been changing a lot from that time until now. When I was racing Eurocup 2.0, one time we were like 48 drivers, I remember. 2008 at Spa. It was a massive level and so many drivers wanted to go in,” he said. “Eurocup was really high level, I would say maybe [comparable] to Formula 4 about the car and the lap times. “Motorsport has changed a lot in the last few years. It's more expensive. At that time, Eurocup was also expensive, but I think Formula 4 is around €700,000 more or less, maybe more now. It's quite expensive. Back then, I think Eurocup was around €300,000 or €250,000, so there was a massive difference. A lot more people could race at that time.” After two and a half years competing in various Formula Renault series, Monrás stepped up to GP3 in 2010. The inaugural season, won by eventual F1 driver Esteban Gutiérrez, came with another steep learning curve. Monrás managed two podiums and a 10th-place finish in the standings, but the step up exposed the limits of what talent alone could achieve in a field packed with hungry, well-backed drivers. “When I raced GP3, that was the first year of the championship, so it was a new championship for all of the teams. I also raced with Arden, which was a new team in the category, so it made it a bit difficult,” he said. “During testing, I remember I was flying in GP3, and then suddenly in some races there was such a huge difference with some other cars and drivers. It was difficult sometimes. … I think this is always present in motorsport in all categories. You will find some kind of differences within cars and teams. It just will always be there.” Challenging as it was, that season had its highs for Monrás. A recovery drive in Spa's characteristic rain remains a fond memory for the Spaniard. “I had a really bad qualifying because there were some yellow flags,” he explained. “Because there were 30 cars, it was easy to find yellow flags if you're waiting for the last minutes in qualifying. I finished [ninth in] race one, and in race two it started raining really heavily after five laps. I went from P10 to P3, nearly fighting for the win in the last lap against Rossi and Tambay. That was a really good race.” After a season in GP3, Monrás moved up a rung on the ladder to Formula Two. At the time, the feeder series landscape was fragmented. GP2 and Formula Renault 3.5 offered established paths to Formula 1, while the MotorSport Vision's FIA Formula Two Championship, which first ran in 2009, aimed to do the same with a more affordable package. “Formula Two at that point was very competitive, economically speaking,” Monrás said. “It was a lot cheaper to race in Formula Two than race in GP2 at that moment or 3.5 because it was like all one team. All the cars were one team with different engineers, and that made it low cost for the time. “A lot of drivers went to it because of that. They were racing in the best tracks, same as World Series and similar to GP2, and the car was competitive. Maybe not as competitive as GP2 or 3.5 because it was a bit slower, but it was really competitive and really fast, on the straight especially.”  “In that time, what they were saying was it was very equal. You had one engineer for three cars, you were sharing data with these three cars, and it was all under the same team. You can always find differences in motorsport. Maybe not a difference to make one car win and one car P15, but you can still always find two-tenths difference in similar cars, and two tenths, sometimes it's a lot of time,” he said. “The cars were on the same team, but each engineer was doing the set-up for his driver. The set-up I was using and maybe the set-up Bortolotti was using, he had won the championship maybe from our different set-ups. Every race, you changed engineers. Every weekend, you were rotating engineers so at the end of the season, everybody worked with everyone.” By 2012, the funding had dried up. Monrás was left sponsorless and unable to compete in Formula Two. He sampled GT racing in the Blancpain Endurance Series and tested with both Audi Sport and Atech GP, but no program materialised. From there, Monrás transitioned into driver coaching and team management – mostly with the AV Formula team owned by his manager, Adrian Vallés – and eventually “moved on” from motorsport around 2017. “I was working also with McLaren Automotive, but it was not motorsport. It was automotive, developing road cars, really competitive cars. After that I decided to stop because I wanted to follow a new career professionally, and I moved onto real estate which I have always been [involved with] because of my family, so that's why I decided to move over,” he said. “I now work in a real estate company which I own with some partners, and that's my day-to-day nowadays.” After years climbing the ladder in lockstep with some of the sport's future stars, Monrás has found a new rhythm – one that's decidedly less fast, but no less his own. Yet his career remains a reminder of the talent that defined an era: a Spaniard who went wheel to wheel with the likes of Ricciardo, Bottas, and Vergne, racing in some of the deepest junior grids of the 2000s and 2010s. In the story of that generation, Monrás may no longer be on track, but he's never far from the memory of it all.

Narrativas analisa os acontecimentos do Brasil e do mundo sob diferentes perspectivas.     Com apresentação de #MadeleineLacsko, o programa desmonta discursos, expõe fake news e discute os impactos das narrativas na sociedade.     Abordando temas como geopolítica, comunicação e mídia, traz uma visão aprofundada   e esclarecedora sobre o mundo atual.     Ao vivo de segunda a sexta-feira às 17h.   Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay:   https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br #Janja #Lula #CartaoCorporativo #PoliticaBrasileira #GastosPublicos #NoticiasBrasil #GovernoLula #Transparencia #Economia #BrasilHoje #PortalDaTransparencia #JanjaLula #DinheiroPublico

Alexandre Garcia comenta sobre gastos do governo Lula, a necessidade de transparência no caso Master e maioridade penal. 

Produzida pela Coordenadoria de TV e Rádio do Superior Tribunal de Justiça (CRTV/STJ), reportagem especial apresenta um panorama dos entendimentos da corte sobre a atividade dos cartórios extrajudiciais no Brasil. .Entre os pontos abordados da jurisprudência do STJ, a matéria destaca precedentes envolvendo a configuração de nepotismo póstumo em nomeações e a definição do dever de divulgação de dados dos cartórios em portais da transparência do Poder Judiciário.

En este episodio del podcast de ACHO hematología, el Dr. Juan Manuel Herrera, especialista en Hematología y Oncología y coordinador de la Unidad de Trasplante de Médula Ósea y Terapia Celular de la Clínica Imbanaco en Cali, lidera este episodio dedicado a revisar los avances más relevantes en trasplante de médula ósea y terapias celulares. La dinámica del pódcast se centra en un recorrido histórico y actualizado de la especialidad, desde los primeros intentos de trasplante hasta las innovaciones más recientes en profilaxis y tratamiento de la enfermedad de injerto contra huésped (EICH), la expansión del pool de donantes, la integración de terapias génicas y la irrupción de las CAR-T. Se destaca el hito del E. Donnall Thomas, ganador del Premio Nobel por demostrar la curación de pacientes con anemia aplásica mediante trasplante, y cómo hoy el campo evoluciona hacia un modelo integral de terapia celular.En la conversación se abordan los cambios en la profilaxis de EICH con el uso de ciclofosfamida post-trasplante, que ha ampliado el acceso al trasplante alogénico incluso en donantes no emparentados; los avances terapéuticos con fármacos como ruxolitinib (a partir de los estudios REACH), belumosudil, itacitinib y abatacept; y la aprobación por la FDA de terapias innovadoras como células mesenquimales para EICH aguda pediátrica y terapias génicas para anemia de células falciformes en 2023. Asimismo, se analiza el papel de compuestos como UM171 en la expansión de sangre de cordón umbilical, la reducción de toxicidad en el acondicionamiento con treosulfán y la creciente integración de las terapias CAR-T en mieloma múltiple, linfoma y leucemia linfoide aguda, aclarando que no reemplazan el trasplante sino que lo complementan. Finalmente, se enfatiza cómo la mejora en soporte clínico, control infeccioso y experiencia de los equipos ha disminuido la mortalidad y ampliado las indicaciones, consolidando una práctica más segura y personalizada.Dentro de su conversación, se plantearon las siguientes preguntas:¿Cómo ha evolucionado el trasplante de médula ósea desde sus inicios hasta la actualidad?¿Qué impacto ha tenido la ciclofosfamida post-trasplante en la ampliación del pool de donantes?¿Cuáles son los avances más importantes en la profilaxis y el tratamiento de la EICH?¿Qué papel cumplen medicamentos como ruxolitinib, belumosudil, itacitinib y abatacept en la EICH?¿Qué relevancia tiene la aprobación de terapias génicas para anemia de células falciformes?¿Cómo ha influido el desarrollo de compuestos como UM171 en el trasplante con sangre de cordón umbilical?¿Qué ventajas ofrece el treosulfán frente a los esquemas clásicos de acondicionamiento?¿Las terapias CAR-T reemplazarán al trasplante o actúan como complemento?¿Cuáles son los principales riesgos actuales de las terapias CAR-T?¿Cómo han impactado estos avances en la supervivencia y calidad de vida de los pacientes?Fecha de grabación: 30 de septiembre de 2025.Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.

Ever notice how your Etsy shop gets a lot of "Add to Cart" activity… but not a lot of purchases? You're not alone. In this episode, we break down why shoppers use "Add to Cart" so often in ecommerce , and why it doesn't mean they're ready to buy. Here is that creepy video I talked about - brace yourself. - https://www.youtube.com/watch?v=Ntf5_ue2Lzw&t=294s Join my skool group if your not too creeped out - https://www.skool.com/grow-my-etsy-shop-3051  

Álvaro Gribel, repórter especial e colunista do Estadão, comenta os principais assuntos da Economia e Política nacionais no Jornal Eldorado, às 2ªs, 4ªs e 6ªs, às 8h30.See omnystudio.com/listener for privacy information.

@katiucha e @OdeioPePe querem saber: você assumiria uma traição em rede internacional para ter seu paquera de volta? Se o crime não compensa, como uma cartãozeira ganhou medalha de ouro? Esse e outros questionamentos no episódio 113 do VortexOferta especial nos planos usando o nosso link no Nordvpn: https://nordvpn.com/vortexpodou CUPOM: VORTEXPODAcesse o link do Vortex e ganhe DESCONTO ESPECIAL  na sua matrícula na Alura: https://www.alura.com.br/vortexou CUPOM: VORTEX Host: Katiucha Barcelos. Instagram: @katbarcelos | Twitter/X: @katiuchaCo-Host: Pedro Pinheiro. Instagram: @odeiopepe | Twitter/X: @OdeioPePeInstagram: @feedvortexBluesky: @feedvortex.bsky.sociaTwitter: @feedvortexTiktok: @feedvortexReddit: r/feedvortexGrupo paralelo não-oficial do Vortex no telegram: https://t.me/+BHlkG92BfPU5ZjdhEsse grupo é dos ouvintes, para os ouvintes e pelos ouvintes. Não temos qualquer afiliação oficial ou responsabilidade por QUALQUER COISA falada neste grupoLink do post do episódio nas redes sociais:InstagramTwitterLinks comentados no episódio:Pronuncia do Sobrenome do LucasLucas Pinheiro cantando o hino do Brasil  Localização perfeita para uma olimpíada de inverno Acusação de trapaça vira polêmica no curling com xingamento e pedido de VARCurling: Canadá vive nova polêmica nos Jogos de Inverno de 2026 após acusação de trapaça no time masculinoVídeo da atleta canadense também SUPOSTAMENTE usando o dedinhoShaidorov se vestiu como Po , da franquia Kung Fu Panda, durante o evento de gala do Campeonato Mundial de 2025Rotina de Duna do medalhista de ouroAmericano dá mortal na patinação artistica, movimento que foi banido por anosNorueguês ganha medalha e confessa traiçãoResposta da NamoradaFugitivo eslovaco capturado quando tentou assistir hóquei olímpicoBatedora de carteira fa França leva ouroEstoque de camisinhas acaba na Vila Olímpica dos Jogos de Inverno, e 10 mil preservativos são repostos: 'Terminaram em 3 dias'Ex-atleta olímpica alemã revela por que há tantas relações sexuais entre atletas durante os Jogos OlímpicosProdução: Thyara Castro, Bruno Azevedo e Aparecido SantosEdição: Joel SukeIlustração da capa: Brann Sousa 

A study of II Samuel 6 on the importance of staying with God's Way and not going with worldly methods

Ecoutez L'édito d'Etienne Gernelle du 19 février 2026.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

AITA: For not giving someone my cart at Aldi's, DIRT ALERT: Gene Hackman estate update, an appreciation moment for "The Birdcage," and Jason's upcoming junket trip to Beverly HillsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

recorded 1/21/2026

The Pre-Launch Strategy That Changes Everything What if your audience was already excited to buy before you ever opened the cart? That's the dream, right? No scrambling in the final hours. No sending more emails than you planned. No pushing harder than feels good and still wondering why it's not converting. I'm sitting down with Brenna McGowan, launch strategist and creator of Anticipation Marketing, to talk about the phase of launching most people skip over entirely. And honestly, it's the phase that makes or breaks your results. Here's what I've learned from my own launches and from watching thousands of my students do theirs: most people think they're doing the pre-launch part right. They mention what's coming in the P.S. of an email. They post about it on social and put up a waitlist. They feel like they're doing everything they're supposed to be doing. But then the cart opens and it still feels harder than it should. They're white-knuckling their way through launch week, and by the end of it, they're exhausted and wondering what went wrong. Is it the offer? Is it the audience? Is it just harder to sell right now? Usually, it's none of those things. It's the pre-launch. And that's what we're fixing today. RESOURCES MENTIONED IN THIS EPISODE: You've built something real. Revenue, audience, offers that work. But the results still don't match what you know you're capable of. The Revenue Consistency Formula is a FREE Live training for six-figure female founders who are done with inconsistent results and ready to understand what's out of sync so their messaging, offers, and lead generation can finally work together. Click here to register now. Learn More About Brenna McGowan Find Brenna McGowan on Instagram The Pre-Launch Plan Program HERE ARE THE 3 KEY TAKEAWAYS FROM THIS EPISODE: 1️⃣ A Waitlist Is Not a Pre-Launch — Posting "join the waitlist" isn't warming your audience up in the way you think it is. A real pre-launch builds belief in the problem, belief in the solution, and belief that you are the person to help them get there. When that's in place, you don't have to convince anyone when the cart opens. They're already in. 2️⃣ Sell the Process, Not the Program — During pre-launch, you shouldn't be talking about your course or your offer. Your job is to get your audience to believe in the method behind it. Brenna calls this belief-shifting, and it's the difference between an audience that's ready to buy and one that stays on the fence. 3️⃣ Anticipation Beats Urgency — Emphasizing the countdown used to work, but not anymore. People have been burned by courses and programs that didn't deliver, and they've lost trust in others and in themselves. What works now is building genuine excitement and curiosity so your audience is leaning in and asking when they can buy instead of feeling pushed into a decision. MORE FROM ME Follow me on Instagram @amyporterfield SUBSCRIBE & REVIEW If you loved this episode, please take a moment to subscribe and leave a review on Apple Podcasts! Your support helps us reach more entrepreneurs who need these insights.

What could replace chemotherapy?In this episode of Beyond the Rounds, we explore cellular therapy, CAR-T cell therapy, tumor-infiltrating lymphocytes (TIL), and how modern immunotherapy is reshaping cancer treatment. Dr. Nolan Fisher sits down with hematologist and cellular therapy specialist Dr. Yazan Samhouri of Banner MD Anderson Cancer Center to break down how immune-based cancer treatments differ from traditional chemotherapy — and why the “last resort” label for CAR-T is quickly becoming outdated.This episode is designed for physicians, advanced practice providers, and clinicians who want a practical understanding of where cellular therapies fit in today's oncology landscape.What We Cover:• The difference between chemotherapy, immunotherapy, and cellular therapy• How CAR-T cell therapy works (Chimeric Antigen Receptor T-cells explained)• Tumor-infiltrating lymphocyte (TIL) therapy for solid tumors• Stem cell transplant vs. CAR-T — complementary or competing?• Cytokine release syndrome (CRS) and neurologic toxicity• Patient selection and referral timing• Why earlier referral matters in relapsed/refractory disease• Next-generation CAR-T and multi-antigen targeting• Off-the-shelf cellular therapies and the future of accessKey Topics for Clinicians:Hematologic malignanciesLymphoma and leukemiaMetastatic melanomaRelapsed/refractory cancerBridging therapy during CAR-T manufacturingFDA-approved immunotherapiesCancer clinical trialsMultidisciplinary cancer careAbout Our GuestDr. Yazan Samhouri is a specialist in hematology and cellular therapy at Banner MD Anderson Cancer Center. His clinical focus includes CAR-T therapy, stem cell transplantation, and advanced immunotherapeutic approaches for blood cancers and select solid tumors.DisclaimerThis podcast is intended for educational purposes only and is designed for a clinical audience. Any patient scenarios discussed are modified and de-identified to protect privacy. No protected health information (PHI) is disclosed. The information presented should not replace independent medical judgment or individualized patient care decisions.Subscribe to Beyond the Rounds for physician-focused conversations on clinical innovation, specialty collaboration, and evolving standards of care.

Merci à Thomas !

On this episode Lara and Vyanka talk to Prof Georg Schett from Friedrich-Alexander University all about T cell engaging immunotherapies such as CAR T-cells and their use in the treatment of autoimmune diseases. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

Almudena Grandes (Madrid, 1960-2021) ha sido una escritora extraordinaria, comprometida, una de las mejores narradoras de la última literatura española. Es la autora, entre otros, de 'Las edades de Lulú', 'Malena es un nombre de tango', 'Atlas de geografía humana', 'El corazón helado', 'Los aires difíciles' y de la extraordinaria serie 'Episodios de una guerra interminable', que dejó inacabada. 'Castillos de cartón' se publicó en el año 2004. 

La Universidad de Málaga acogerá una de las dos sedes en Europa de la IUPAC, la organización internacional que coordina y establece los estándares de la investigación química a nivel mundial. La elección de la ciudad andaluza pone fin a casi tres décadas de permanencia de la organización en Estados Unidos y sitúa a Málaga y a nuestro país como un lugar de referencia en la coordinación internacional de la Química. Hemos entrevistado a Javier García Martínez, expresidente de la IUPAC y gran artífice de esta decisión. Verónica Fuentes (SINC) nos ha hablado de los cazadores de eclipses, apasionados de la astronomía que siguen estos breves fenómenos por todo el mundo, y de la oportunidad que se les ofrece en nuestro país con sendos eclipses totales de Sol este año y el próximo, y un tercero anular en 2028. Con testimonios del chileno Alejandro Arroyo y del español Frank Rodríguez. El cloro es un elemento químico con una doble cara: es tóxico y, al mismo tiempo, fundamental para la vida. Bernardo Herradón nos ha contado sus aplicaciones médicas e industriales. Con Jesús Zamora hemos comentado tecnologías y proyectos disruptivos y prometedores que se anuncian, pero no que no terminan de llegar, como la computación cuántica o la colonización de otros mundos. Con Javier Ablanque al mando de nuestra máquina del tiempo hemos viajado a 1936, al frente de la Ciudad Universitaria en Madrid, donde se emplearon libros como parapetos, para conocer la física que hay detrás de un disparo de fusil. Hemos informado del premio Fundación BBVA Fronteras del conocimiento en la categoría de Biología y Biomedicina a Carl June y Michel Sadelain por revolucionar el tratamiento del cáncer a través de la inmunoterapia basada en la modificación genética de células del propio paciente, las llamadas células CAR-T.Escuchar audio

Autoimmune diseases like myasthenia gravis have long forced patients to trade daily function for chronic immunosuppression, but Cartesian Therapeutics is betting that its experimental RNA‑engineered CAR T cells can rewrite that equation. The company's lead experimental therapy, Descartes‑08, is designed to deliver deep, durable remissions through a short course of outpatient infusions that selectively eliminate the plasma cells driving disease, while sidestepping the toxicity and logistical hurdles of conventional DNA‑based CAR T therapies. We spoke to Carsten Brunn, CEO of Cartesian Therapeutics, about how the company's RNA‑engineered CAR T cells target the root cause of autoimmune diseases, data from its phase 2 study in myasthenia gravis, and the potential to expand the approach into myositis and other rare autoimmune indications.

The feature accepts both image and text prompts, but is still in beta at the moment. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Early evidence for CAR T-cell therapy in lupus is compelling. Are you up-to-date? Credit available for this activity expires: 2/9/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/car-t-cells-sle-new-frontier-autoimmunity-2026a10003ow?ecd=bdc_podcast_libsyn_mscpedu

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Anastasios Karadimitris and Maria Carolina Florian on their papers published in Volume 147 Issue 2 of Blood. Dr. Karadimitris' paper "Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia", discusses the success of bispecific CAR-iNKT cells targeting CD19 and CD133 in pre-clinical models, prompting the clinical development of this class of product. Dr. Florian's paper, "A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging" proposes that the Jagged2/Notch interaction is a key regulator of hematopoietic stem cell divisional symmetry during aging and offers insights that may inform strategies to restore regenerative function in aged hematopoiesis. 

Komórki nowotworowe to nie byty obce, ale nasze własne, tyle że zbuntowane.  Zamiast współpracować, odmawiają „honorowej” samodestrukcji (apoptozy), ignorują sygnały z otoczenia i dzielą się wtedy, kiedy nie powinny. – Komórka rakowa jest w sobie zakochana do tego stopnia, że interesuje ją tylko to, żeby siebie powielać – porównuje prof. Kinga Kamieniarz-Gdula z Centrum Zaawansowanych Technologii i Wydziału Biologii UAM w Poznaniu, z którą rozmawiam w najnowszym odcinku. Zdrowe komórki mają fizjologiczny limit podziałów. Po jego przekroczeniu przestają to robić lub umierają. – Natomiast komórki nowotworowe potrafią wyzerować ten licznik i stać się nieśmiertelne. Robią to często przez aktywację enzymu, który nazywa się telomeraza – wyjaśnia uczona. Takie komórki potrafią tworzyć własną sieć naczyń krwionośnych, omijają mechanizmy naprawy DNA i obronę immunologiczną.Słowem: są niezwykle trudnym przeciwnikiem. Mało kto jednak wie, że nowotwory powstają w nas bardzo często – organizm codziennie produkuje tysiące komórek z potencjalnie groźnymi mutacjami – ale zazwyczaj sobie z nimi radzi. Wchodzą do akcji „policjanci” układu odpornościowego, mechanizmy naprawy DNA. W rozmowie porządkujemy współczesne metody leczenia: od wciąż niezwykle skutecznej chirurgii, przez klasyczną chemioterapię i radioterapię, po nowsze terapie celowane oraz immunoterapię – w tym „żywy lek” CAR-T. Niedawno odkryto, że piętą Achillesową komórek rakowych jest końcowy etap przepisywania informacji genetycznej z genu (cząsteczki DNA) na RNA. Większość ludzkich genów ma kilka alternatywnych końców, a wybór tego właściwego może wpływać na końcowy produkt, czyli białko. Aby wykorzystać tę wiedzę w potencjalnej terapii przeciwnowotworowej, prof. Kinga Kamieniarz-Gdula wraz z dr Martyną Plens-Gałąską opracowały innowacyjną metodę do poszukiwań nowych leków, które kierują wyborem, gdzie kończy się gen. Uczone będą kontynuowały nowatorskie badania, m.in. dzięki kolejnemu grantowi ERC uzyskanemu przez prof. Kamieniarz-Gdulę, tym razem Proof of Concept, pozyskanemu na projekt “Biologia molekularna w terapii przeciwnowotworowej – poszukiwania nowych leków, które kierują wyborem, gdzie kończy się gen”. W zespole pracują wspólnie z dr Agatą Stępień.W odcinku usłyszycie też dlaczego sen, ruch, unikanie kancerogenów oraz ogólnie zdrowy styl życia naprawdę mają znaczenie – bo wspierają właśnie te ciche, codzienne interwencje naszego organizmu. Poznacie barwne metafory mechanizmów stojących za genetyką, opowieść o tym, jak to jest wrócić z Oxfrodu nad Wisłę, a także pochwałę badań podstawowych. Polecamy!W opisie wykorzystaliśmy fragmenty informacji prasowej Uniwersytetu im. Adama Mickiewicza. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping the landscape of drug development, regulatory scrutiny, and corporate strategies.At the forefront is Madrigal Pharmaceuticals' strategic acquisition of Ribo Therapeutics' preclinical siRNA programs, valued at $4.4 billion. This move aims to fortify Madrigal's liver disease drug portfolio alongside its promising candidate, resmetirom. By expanding into RNA-based therapies, Madrigal highlights an industry trend focused on gene silencing techniques to target genetic diseases more precisely.Turning to Moderna, it faces a regulatory hurdle as the FDA issued a refusal-to-file letter for its mRNA-based flu vaccine. The regulator's concerns about the trial design, specifically the use of a licensed standard-dose seasonal influenza vaccine as a control arm, emphasize the complexities of advancing mRNA technologies beyond COVID-19 applications. This situation underscores the necessity for meticulous trial designs that align with evolving regulatory standards.In cell therapy, allogeneic CAR-T treatments are gaining attention as companies strive to make these therapies more accessible by using T cells from healthy donors, rather than modifying a patient's cells. Despite technical challenges like graft-versus-host disease and immune rejection, these treatments promise streamlined manufacturing and reduced costs, marking a significant evolution from the pioneering autologous CAR-T success with Emily Whitehead in 2012. Eli Lilly's entry into CAR T-cell therapy through a $2.4 billion acquisition of Orna represents an ambitious expansion into autoimmune therapies. This strategic move exemplifies a broader trend where companies diversify portfolios to include emerging therapeutic modalities promising transformative impacts on patient care.In respiratory medicine, Upstream Bio's phase 2 trial of its TSLP receptor agonist showed encouraging results in reducing asthma exacerbations, comparable to Tezspire. However, falling short of best-case scenarios leaves room for competitors to present more compelling data. This illustrates the competitive nature of asthma treatment development and the ongoing quest for superior therapeutic options.A critical regulatory update arises from the NIH's decision to halt the Xarelto arm of a stroke prevention trial due to safety concerns. This decision highlights the indispensable role of independent monitoring committees in ensuring patient safety and meaningful clinical trial outcomes.On the corporate front, AstraZeneca has articulated an ambitious goal to achieve over 25 blockbuster drugs by 2030 as part of its strategy to reach $80 billion in revenue. This vision underscores the importance of innovation and strategic planning in sustaining growth within an increasingly competitive market.Fujifilm Biotechnologies' completion of its £400 million expansion project in the UK is another notable development, signaling robust investment in antibody production capabilities. This expansion positions Fujifilm as a key player in biopharmaceutical contract manufacturing and underscores the growing demand for flexible production technologies.The biotech sector is also witnessing significant activity with Pelage making strides in addressing hair loss through promising candidate developments. The market's enthusiasm for innovative solutions beyond traditional treatments reflects a broader demand for cutting-edge approaches to longstanding medical challenges.In obesity treatment, Novo Nordisk and Eli Lilly continue to lead with notable advancements. Novo Nordisk's recent developments with its Wegovy pill have been positively received, yet analysts question if this will suffice in maintaining their competitive edge given the dynamic nature of this therapeutic areSupport the show

Welcome to Impact Theory with Tom Bilyeu! In this eye-opening episode, Tom Bilyeu and co-host Drew tackle some of the most pressing—and controversial—headlines rocking the world this week. From Big Tech giants like Meta facing landmark lawsuits over the mental health impact of social media on kids, to explosive rumors about cancer cures being unleashed after the US's exit from the WHO, no stone is left unturned. Tom Bilyeu breaks down what's really behind these medical breakthroughs, debunking online conspiracies and explaining the critical roles of the FDA and Big Pharma. The conversation gets real about the unintended consequences of social media on developing minds, whether government intervention is the answer, and how parents can navigate the digital minefield. The hosts also deliver in-depth commentary on global power shifts, including China's economic maneuvers and Japan's political realignment, as well as the seismic advancements in AI technology that are set to reshape creative industries—and possibly life as we know it. To cap it off, Tom Bilyeu and Drew explore SpaceX's renewed focus on building a city on the moon, pondering what it means for humanity's future among the stars. Whether you're curious about the facts behind viral threads, anxious about the impact of tech on the next generation, or just want a fresh take on global headlines, this episode has something for everyone. Let's dive in! Quince: Free shipping and 365-day returns at https://quince.com/impactpodShopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impactKetone IQ: Visit https://ketone.com/IMPACT for 30% OFF your subscription orderIncogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impactBlocktrust IRA: Get up to $2,500 funding bonus to kickstart your account at https://tomcryptoira.comNetsuite: Right now, get our free business guide, Demystifying AI, at https://NetSuite.com/TheoryHuel: High-Protein Starter Kit 20% off for new customers at https://huel.com/impact code impact What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER:  https://tombilyeu.com/zero-to-founder?utm_campaign=Podcast%20Offer&utm_source=podca[%E2%80%A6]d%20end%20of%20show&utm_content=podcast%20ad%20end%20of%20show SCALING a business: see if you qualify here.:  https://tombilyeu.com/call Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here.: https://tombilyeu.com/ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Big Tech lawsuit, social media addiction, mental health, Big Pharma, cancer cures, World Health Organization (WHO), US healthcare, FDA, immunotherapy, mRNA cancer vaccines, CAR-T cell therapy, KRAS inhibitors, drug approvals, government incentives, socialism, AI breakthroughs, video AI, creative industry, China-US relations, de-dollarization, US debt, China demographics, Japan politics, sushi-fication of Japan, immigration, education policy, brain development, parental control, government regulation, space exploration, Elon Musk moon base. Learn more about your ad choices. Visit megaphone.fm/adchoices

Synopsis: At the heart of JPM 2026's biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could reshape medicine. Fred traces his journey from medical school in Brazil to consulting at BCG, venture capital, and ultimately founding multiple companies—sharing why following curiosity, not rigid career ladders, shaped his path. Fred dives deep into the bottlenecks holding back traditional CAR-T therapies—manufacturing complexity, cost, hospitalization, and toxicity—and explains how Artiva's off-the-shelf NK-cell platform aims to change the paradigm. The discussion explores why rheumatoid arthritis became Artiva's lead indication, how immune “resets” could redefine autoimmune care, and what's ahead in 2026 as the company prepares registrational trials and expands its basket studies across lupus, myositis, scleroderma, and more. The episode closes with rapid-fire takes on AI in drug development, China's accelerating biotech engine, rare disease trial models, and the strategic principles founders should follow when choosing indications and building durable platforms. Biography: Fred Aslan, M.D., has a 20-year track record as an executive and investor in the life sciences industry. He was most recently President and CBO at Vividion Therapeutics, where he was responsible for business development, finance, alliance and project management, and operations. Dr. Aslan had the opportunity to lead Vividion's Series B financing and $135M-upfront collaboration with Roche. Prior to Vividion, Dr. Aslan had a 12-year affiliation with Venrock. Initially he was an investor from 2006 to 2013, when he cofounded and served as a board member of Receptos Pharmaceuticals (acquired by Celgene for more than $7 billion). Dr. Aslan led Venrock's investment in Zeltiq (acquired by Allergan for more than $2 billion) and was involved in the early formation of Fate Therapeutics. Subsequently as an entrepreneur from 2013 to 2018, he was CEO of Adavium Medical, a Brazilian medical device company, which he grew from zero to 350 employees, sales of over US$40 million, and fully integrated R&D, manufacturing, and commercial capabilities. Prior to Venrock, Dr. Aslan was Director of Business Development and Head of Investor Relations for CuraGen, a Nasdaq-listed oncology-focused biotech company. Prior to CuraGen, he was a consultant at Boston Consulting Group (BCG). Dr. Aslan holds a B.S. in biology from Duke University, an M.D. from Yale School of Medicine, and an MBA from Harvard Business School.

Is Artificial Intelligence actually helping cancer patients, or is it just noise? In this episode of The Patient From Hell, Samira sits down with Dr. Shadi Nabhan to separate the Hype from the Reality in 2026.We discuss the massive evolution in oncology—from the "library days" of 1995 to the AI-driven diagnostics of today. Dr. Shadi shares his "Airport Analogy" for navigating a cancer diagnosis, offers a life-changing reframe on how we view advanced disease (it's not just "curable" vs. "terminal"—it can be "controllable"), and gives his #1 piece of advice for selecting a medical team that will actually show up for you when things get hard.Key Topics Discussed:AI in 2026: How doctors use AI to simplify complex terms like CAR T-cell therapy and why patients need to "trust but verify" AI-generated medical advice.The "Controllable" Reframe: Why treating metastatic cancer like diabetes or hypertension changes the patient experience.Navigating the "Airport": Why the healthcare system feels like being dropped in a foreign airport without a map.Advice for the Industry: What Healthcare Systems and Pharma companies need to change right now regarding clinical trials and drug pricing.About Today's Guest Dr. Chadi Nabhan:Dr. Chadi Nabhan is a board-certified hematologist, oncologist, and the Chief Medical Officer at Ryght, Inc., where he leads the integration of Generative AI into clinical research to accelerate the delivery of lifesaving therapies. With a career spanning leadership roles at Caris Life Sciences and the University of Chicago, Dr. Nabhan is a prolific researcher with over 300 publications and a prominent author whose work focuses on the intersection of medicine, justice, and technology.AI Visionary: Leading the charge in using AI to optimize clinical trials and patient outcomes.Expert Clinician: Trained at Northwestern and Harvard, with decades of experience in malignant hematology.Renowned Author: Published three books with Johns Hopkins University Press, including The Cancer Journey and the forthcoming AI and Cancer Care (2026).Podcast Host: Voice of the popular weekly series Healthcare Unfiltered.Quotes from the Episode:"We cure more patients than we have ever dreamt of... Women who are affected by breast cancer today are more likely to be completely cured." "Availability is key. Are they going to really pick up the phone and talk to you when you need them?"00:00 - The reality of the cancer journey (It's not smooth sailing)01:00 - Intro: Dr. Shadi Nabhan & The Fun Factor01:25 - AI in Healthcare: Hype, Hope, and Reality04:15 - How doctors use AI to explain complex therapies06:38 - Warning for patients using AI: "Garbage in, Garbage out"08:45 - The Evolution of Medicine: 1995 vs. 202613:00 - The "Airport Analogy": Why patients feel lost17:30 - MUST WATCH: Reframing "Terminal" cancer as "Controllable"21:30 - Advice for Healthcare Leaders: Agility & Patient Involvement23:50 - Advice for Pharma: Drug Pricing & Accelerating Innovation26:00 - The #1 criteria for picking your medical team28:18 - The importance of Second Opinions28:50 - What to expect in late 2026: AI in Cancer Care Book

In the ever-evolving world of implement technology, a Saskatchewan-based company is looking to clear things up for growers. At the Western Canadian Crop Production Show in Saskatoon, Sask., Brad Reykdal of AgVision joined RealAgriculture’s Amber Bell to discuss AgVision HD. This digital implement camera system was designed to address a void in the Canadian agricultural... Read More

As cell and gene therapies continue to deliver promising clinical results, manufacturing remains one of the biggest barriers to broader commercialization. Persistent challenges around cost, complexity, labor intensity, and vein-to-vein timelines—particularly for autologous CAR-T therapies—are limiting the industry's ability to scale beyond niche and last-line indications. Addressing these constraints will be critical if CGTs are to move earlier in treatment paradigms and reach more patients globally. In this episode of Off Script, we spoke with Jon Ellis, CEO of Trenchant BioSystems, about the current state of cell and gene therapy manufacturing and where the industry must go next. The conversation explores why traditional centralized manufacturing models are struggling to scale, how automation and digital batch records can significantly compress manufacturing timelines, and how emerging platforms are rethinking cell recovery, analytics integration, and starting material strategies.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Arcellx. She also discusses cell therapy funding cycles and big pharma, the autologous versus allogeneic divide, why in vivo CAR-T therapies could be a game changer, what the FDA's focus on cell and gene therapies could mean for U.S. competition, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Ready to make 2026 the year your route runs smoother, faster, and with less strain? We're sharing the exact tools that pay you back in minutes saved and backs spared, plus how to pick the right version for your truck, your clients, and your local conditions.We start with the true workhorse: your pole. Carbon fiber has become the smartest upgrade for daily service thanks to its lighter weight, stiffness, and durability. You'll hear how Primate's vertical lever locks and 3-piece reach let you cover most pools from one side while fitting comfortably in short beds. Then we break down the vacuum landscape. Riptide and Hammerhead remain the heavy hitters with reliable carts and power, but cordless heads like the Bottom Feeder and Shrimp now level up with a cartridge filter assembly that captures dirt down to fine microns while still gobbling leaves. If you want less setup and more clean, this change is a big win.Next, we get practical about skimming and testing. The Piranha 2 quick-flip leaf rake edges out the Red Baron for its balanced lip and easy dumps that save precious seconds on every basket-empty day. For water chemistry, the LaMotte ColorQ 2X Pro 9 delivers photometer accuracy without Spin Touch pricing, and crucially adds copper and iron testing to diagnose staining and metals from fill water. We also cover a field favorite: the Multi-Torque socket set that turns stubborn filter lids into a quick drill job and keeps knuckles intact, plus the glove setup that protects hands year-round—light nitrile-coated pairs for daily work and long-cuff Atlas 772s for cold mornings.• Carbon fiber poles with fast vertical locks and smart sizing• Cart vacs vs cordless heads for debris and dirt pickup• Bottom Feeder and Shrimp with cartridge filter assembly• Leaf rakes compared: Piranha 2 quick-flip vs Red Baron• Photometry: ColorQ 2X Pro 9 vs Spin Touch use cases• Multi-Torque sockets for faster, safer filter service• Hand protection: nitrile-coated gloves and cold-weather picks• Discounts and part numbers to make buSend us a textSupport the Pool Guy Podcast Show Sponsors! HASA https://bit.ly/HASAThe Bottom Feeder. Save $100 with Code: DVB100https://store.thebottomfeeder.com/Try Skimmer FREE for 30 days:https://getskimmer.com/poolguy Get UPA Liability Insurance $64 a month! https://forms.gle/F9YoTWNQ8WnvT4QBAPool Guy Coaching: https://bit.ly/40wFE6y

Broadcast from KSQD, Santa Cruz on 3-05-2026: >ul> Dr. Dawn presents a whimsical "theme park tour" of the upper gastrointestinal tract, from saliva production triggered by sight and smell of food, through the esophageal sphincter's iris-like opening, into the stomach's pH-1 acid bath where parietal cells produce 3,000 mg of hydrochloric acid per meal. She explains protective mechanisms including the bicarbonate layer beneath stomach mucus, H. pylori's role in ulcers, and how H2 blockers and proton pump inhibitors work—cautioning about long-term PPI effects on B12 and calcium absorption. The tour continues through the pylorus into the duodenum where pancreatic enzymes and bile converge, then along the 23-foot small intestine with its tennis-court surface area of villi absorbing nutrients, iron in the duodenum, most nutrients in the jejunum, and B12 requiring intrinsic factor in the ileum. Dr. Dawn explains why pancreatic cancer—projected to become the second leading cause of cancer death by 2030—is so deadly, using a medieval castle metaphor. The tumor microenvironment acts as an impenetrable moat of desmoplastic stroma made of fibroblasts, collagen, and hyaluronic acid that blocks drugs and immune cells. Over 90% of cases have K-RAS mutations acting as growth accelerators that also thicken this protective barrier and increase CD47 "don't eat me" signals. She discusses emerging treatments including K-RAS inhibitors, PARP inhibitors for BRCA mutations, and combination immunotherapies showing 67% response rates, while noting that CAR T-cell therapy and checkpoint inhibitors alone fail because they cannot penetrate the stroma. Dr. Dawn summarizes Duke researcher Herman Ponzer's work using doubly-labeled water to measure total energy expenditure, revealing that humans burn 20-60% more calories than other great apes when adjusted for body mass. His surprising finding: Hadza hunter-gatherers walking 8-14 kilometers daily burn the same calories as sedentary Americans—the body compensates by reducing energy spent on inflammation and stress responses. This "constrained energy expenditure" model explains why exercise alone doesn't cause weight loss, though it remains crucial for preventing weight gain, reducing disease risk, and potentially tamping down harmful stress responses.

Unlock the Future of Brand Growth Discover what's changing fastest in how brands grow today, straight from industry leaders who are shaping modern commerce. The RETHINK Retail Podcast takes you behind the scenes of marketplace strategies, ecosystem-driven growth, and omnichannel success. Learn from the expertise of Tim Derner of Authentic Brands Group and Remington Tonar of Cart.com as they explore: - Marketplace acceleration: How Amazon, TikTok Shop, and global platforms are driving brand expansion. - Ecosystem advantage: Why combining brands, IP, talent, entertainment, and retail partnerships creates outsized impact. - Omnichannel pitfalls: The most common traps brands fall into when trying to be everywhere at once. - AI in operations: Where automation and intelligence are quietly improving efficiency without being the headline. Whether you're a brand manager, retailer, or commerce innovator, this episode provides actionable insights to help your brand scale globally, simplify operations, and stay ahead of the competition.

This month Alt.Latino's been looking at the music of Venezuela from a lot of different angles. For this episode, we've invited trumpet player and producer Ella Bric to be our guest DJ. She shared what she thinks are the most socially, culturally and politically impactful pieces of music to come out of Venezuela in the last half century.Ella Bric grew up in a migrant-rich town in Venezuela called San Antonio de los Altos, surrounded by a culturally-minded, socially conscious community. She's now based in New York, and in recent years has positioned herself as a prolific producer on the rise in the Latin music space. In 2018, she won a Latin Grammy for Producer of the Year, and she says her art comes from a curiosity about the state of the world and her desire to reflect that.(00:00) Introduction(01:46) La Vida Bohème, 'Hornos del Cal'(06:41) Betsayda Machado & Parranda el Clavo, 'Sentimiento'(11:35) María Rodríguez, 'Los Dos Titanes'(15:11) Ali Primera, 'Techos de Cartón'(19:52) Linda Briceño & Orlando Watson, 'Unfinished Song'(24:38) Desorden Público, 'Politicos Paraliticos'(27:36) Bucle Lunar, 'Subió El Maldito Dolar'This podcast episode was produced by Noah Caldwell. The executive producer of NPR Music is Suraya Mohamed.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

This month, the gals invite Brandon Schexnayder from Southern Gothic on to chitchat about ghost gaslighting, sexy sheep, party raccoons, a porta-potty problem, and a brand-new fear for Amanda. Tune in for January's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.